Public Profile

Purdue Pharma L.P.

Purdue Pharma L.P., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1892, the company has established itself as a leader in pain management and addiction treatment, with a focus on developing innovative therapies. Purdue Pharma is best known for its flagship product, OxyContin, which revolutionised pain relief but also sparked significant discussions around opioid use and addiction. With a commitment to addressing public health challenges, Purdue Pharma has expanded its portfolio to include a range of medications aimed at treating various conditions, including opioid use disorder. The company has made notable strides in research and development, positioning itself as a key contributor to the ongoing dialogue about responsible pain management. Through its dedication to improving patient outcomes, Purdue Pharma continues to navigate the complexities of the pharmaceutical landscape.

DitchCarbon Score

How does Purdue Pharma L.P.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Purdue Pharma L.P.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Purdue Pharma L.P.'s reported carbon emissions

Purdue Pharma L.P., headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that Purdue Pharma may not have established formal commitments to reduce its carbon footprint or engage in climate action at this time. As the pharmaceutical industry increasingly focuses on sustainability, it will be important for Purdue Pharma to consider developing and communicating its climate commitments to align with industry standards and expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Purdue Pharma L.P.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Purdue Pharma L.P. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Purdue Pharma L.P. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Taking Reduction Action?

Similar Organizations

Paladin Labs Inc.

CA
Chemicals nec
Updated about 1 month ago
DitchCarbon Score

Corium, LLC

US
Chemicals nec
Updated 10 days ago

Eurand, Inc.

US
Chemicals nec
Updated 15 days ago

RVL Pharmaceuticals plc

US
Chemicals nec
Updated 9 days ago

Takeda

JP
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

BioDelivery Sciences International, Inc.

US
Chemicals nec
Updated about 1 month ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers